{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:51:34Z","timestamp":1791993094450,"version":"4.4.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/cid\/ciag553","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:19:42Z","timestamp":1788520782000},"source":"Crossref","is-referenced-by-count":0,"title":["Oral Fosfomycin for Complicated Urinary Tract Infection Remains a Murky Issue"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-9099","authenticated-orcid":false,"given":"Barbara W","family":"Trautner","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine and VA St Louis Health Care System , St Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas W","family":"Cortes-Penfield","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-3576","authenticated-orcid":false,"given":"Kalpana","family":"Gupta","sequence":"additional","affiliation":[{"name":"Infectious Diseases, VA Boston HCS and Boston University Chobanian & Avedisian School of Medicine , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Lavergne","sequence":"additional","affiliation":[{"name":"Division of Medical Microbiology and Infection Control, Department of Pathology & Laboratory Medicine, Vancouver General Hospital, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Infectious Diseases Society of America Department of Clinical Affairs and Practice Guidelines, (IDSA), Arlington, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2026101411375423200_ciag553-B1"},{"key":"2026101411375423200_ciag553-B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2026.108826","article-title":"Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infections: a randomized controlled trial","volume":"170","author":"Angkanavisan","year":"2026","journal-title":"Int J Infect Dis"},{"key":"2026101411375423200_ciag553-B3","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciag345","article-title":"Fosfomycin as oral transition therapy versus continued intravenous \u03b2-lactams for complicated urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacterales: a multicenter, open-label, randomized controlled trial","author":"Seo","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026101411375423200_ciag553-B4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026101411375423200_ciag553-B5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/jac\/dkad147","article-title":"Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial","volume":"78","author":"Sojo-Dorado","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026101411375423200_ciag553-B6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciab934","article-title":"Fosfomycin vs ciprofloxacin as oral step-down treatment for Escherichia coli febrile urinary tract infections in women: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"75","author":"Ten Doesschate","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026101411375423200_ciag553-B7","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01677-23","article-title":"Daily fosfomycin versus levofloxacin for complicated urinary tract infections","volume":"14","author":"Rouphael","year":"2023","journal-title":"mBio"},{"key":"2026101411375423200_ciag553-B8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","article-title":"Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections","volume":"392","author":"Daneman","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101411375423200_ciag553-B9","first-page":"96","article-title":"Fosfomycin versus ampicillin in the treatment of acute pyelonephritis","volume":"7","author":"Ode","year":"1988","journal-title":"Chemioterapia"},{"key":"2026101411375423200_ciag553-B10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00775-17","article-title":"Pharmacokinetics, safety, and tolerability of single-dose intravenous (ZTI-01) and oral fosfomycin in healthy volunteers","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101411375423200_ciag553-B11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00903-19","article-title":"Unexpected activity of oral fosfomycin against resistant strains of Escherichia coli in murine pyelonephritis","volume":"63","author":"Pourbaix","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101411375423200_ciag553-B12","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10096-019-03679-9","article-title":"A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis","volume":"38","author":"Cattrall","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026101411375423200_ciag553-B13","volume-title":"Performance standards for antimicrobial susceptibility testing; M100-ED36","author":"Clinical and Laboratory Standards Institute","year":"2026","edition":"26th ed"},{"key":"2026101411375423200_ciag553-B14","author":"The European Committee on Antimicrobial Susceptibility Testing"},{"key":"2026101411375423200_ciag553-B15","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03363-22","article-title":"Fosfomycin disk diffusion testing among Klebsiella pneumoniae results in frequent inner colonies and categorical disagreement based on conflicting breakpoint organization recommendations","volume":"11","author":"Bixby","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026101411375423200_ciag553-B16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00464-18","article-title":"Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants","volume":"62","author":"Wenzler","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101411375423200_ciag553-B17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02102-19","article-title":"Ex vivo urinary bactericidal activity and urinary pharmacodynamics of fosfomycin after two repeated dosing regimens of oral fosfomycin tromethamine in healthy adult subjects","volume":"64","author":"Wenzler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101411375423200_ciag553-B18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.44495","article-title":"Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement","volume":"7","author":"Nelson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026101411375423200_ciag553-B19","doi-asserted-by":"crossref","first-page":"ciag481","DOI":"10.1093\/cid\/ciag481","article-title":"Infectious Diseases Society of America 2026 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2026","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag553\/71947525\/ciag553.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag553\/71947525\/ciag553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:38:01Z","timestamp":1791992281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciag553\/8916510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag553","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"article-number":"ciag553"}}